Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c

Zhang,Jingming; Tan,Yingying; Yao,Fanrong; Zhang,Qi

doi:10.3892/mmr.2012.1015

Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-α and SREBP-1c

Authors:
- Jingming Zhang
- Yingying Tan
- Fanrong Yao
- Qi Zhang
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Basic Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China, Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58102, USA
Published online on: July 31, 2012 https://doi.org/10.3892/mmr.2012.1015
Pages: 815-820

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pathophysiology of non-alcoholic fatty liver disease remains incompletely elucidated, and available treatments are not entirely satisfactory. Polydatin, a stilbenoid compound derived from the rhizome of Polygonum cuspidatum, has been recognised to possess hepatoprotective and anti-inflammatory activities. The purpose of the present study was to determine whether polydatin has a protective effect against hepatic steatosis induced by a high-fat diet (HFD) and to elucidate its underlying molecular mechanisms in rats. Male Sprague-Dawley rats were randomly divided into four groups, including normal control, HFD model and polydatin‑treated groups with polydatin levels of 30 and 90 mg/kg. Following the experimental period, plasma total cholesterol (TC), triglyceride (TG) and hepatic lipid concentrations were determined. To identify a possible mechanism, we examined the changes in liver tumor necrosis factor-α (TNF-α), lipid peroxidation levels and sterol-regulatory element binding protein (SREBP-1c) mRNA and its target genes. Both 30 and 90 mg/kg polydatin treatment alleviated hepatic steatosis and reduced plasma and liver TG, TC and free fatty acid (FFA) concentration significantly in HFD rats. In addition, TNF-α, and malondialdehyde and 4-hexanonenal levels were markedly suppressed by polydatin in the liver of HFD-fed rats. Polydatin also decreased the gene expression of SREBP-1c and its target genes involved in lipogenesis, including fatty acid synthase (FAS) and stearoly-CoA desaturase 1 (SCD1) in HFD-fed rats. These results suggest that the protective effects of polydatin against HFD-induced hepatic steatosis may be partly associated with reduced liver TNF-α expression, lipid peroxidation level and SREBP-1c-mediated lipogenesis.

View Figures

View References

1	Duvnjak M, Lerotić I, Barsić N, Tomasić V, Virović Jukić L and Velagić V: Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 13:4539–4550. 2007.PubMed/NCBI
2	Angulo P: Non-alcoholic fatty liver disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
3	Yeh MM and Brunt EM: Pathology of non-alcoholic fatty liver disease. Am J Clin Pathol. 128:837–847. 2007. View Article : Google Scholar : PubMed/NCBI
4	Farrell GC and Larter CZ: Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 43:S99–S112. 2006. View Article : Google Scholar : PubMed/NCBI
5	Postic C and Girard J: The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab. 34:643–648. 2008. View Article : Google Scholar : PubMed/NCBI
6	Ayyad C and Andersen T: Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev. 1:113–119. 2000. View Article : Google Scholar : PubMed/NCBI
7	Xue L: Progress in the pharmacological study of Chinese herbal drug: Polygonum cuspidatum. Zhongguo Zhong Yao Za Zhi. 25:651–653. 2000.PubMed/NCBI
8	Luper S: A review of plants used in the treatment of liver disease: part two. Altern Med Rev. 4:178–188. 1999.PubMed/NCBI
9	Kimura Y: Pharmacological studies on resveratrol. Methods Find Exp Clin Pharmacol. 25:297–310. 2003. View Article : Google Scholar : PubMed/NCBI
10	Zhang H, Dou C and Gu F: Advances in the study on pharmacological actions of Polygonum cuspidatum Sieb: clearing heat and detoxication. Zhong Yao Cai. 26:606–610. 2003.PubMed/NCBI
11	Huang ZS, Wang ZW, Liu MP, Zhong SQ, Li QM and Rong XL: Protective effects of polydatin against CCl(4)-induced injury to primarily cultured rat hepatocytes. World J Gastroenterol. 5:41–44. 1999.PubMed/NCBI
12	Ji H, Zhang X, Du Y, Liu H, Li S and Li L: Polydatin modulates inflammation by decreasing NF-κB activation and oxidative stress by increasing Gli1, Ptch1, SOD1 expression and ameliorates blood-brain barrier permeability for its neuroprotective effect in pMCAO rat brain. Brain Res Bull. 87:50–59. 2012.PubMed/NCBI
13	Du J, Sun LN, Xing WW, et al: Lipid-lowering effects of polydatin from Polygonum cuspidatum in hyperlipidemic hamsters. Phytomedicine. 16:652–658. 2009. View Article : Google Scholar
14	Xing WW, Wu JZ, Jia M, Du J, Zhang H and Qin LP: Effects of polydatin from Polygonum cuspidatum on lipid profile in hyperlipidemic rabbits. Biomed Pharmacother. 63:457–462. 2009.
15	Zhang Q, Zhao Y, Zhang DB and Sun LJ: Effect of Sinai san decoction on the development of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 11:1392–1395. 2005. View Article : Google Scholar : PubMed/NCBI
16	Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
17	Folch J, Lees M, Sloane and Starley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 226:497–509. 1957.
18	Bartlett GR: Phosphorous assay in column chromatography. J Biol Chem. 234:466–468. 1959.PubMed/NCBI
19	Zhang Q and Tan Y: Nerve growth factor augments neuronal responsiveness to noradrenaline in cultured dorsal root ganglion neurons of rats. Neuroscience. 193:72–79. 2011. View Article : Google Scholar : PubMed/NCBI
20	Zhang Q, Yao F, Raizada MK, O'Rourke ST and Sun C: Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 104:1421–1428. 2009. View Article : Google Scholar : PubMed/NCBI
21	Diehl AM, Li ZP, Lin HZ and Yang SQ: Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut. 54:303–306. 2005. View Article : Google Scholar : PubMed/NCBI
22	Tilg H and Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 343:1467–1476. 2000. View Article : Google Scholar : PubMed/NCBI
23	Crespo J, Cayon A, Fernandez-Gil P, et al: Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology. 34:1158–1163. 2001. View Article : Google Scholar : PubMed/NCBI
24	Abiru S, Migita K, Maeda Y, et al: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 26:39–45. 2006. View Article : Google Scholar : PubMed/NCBI
25	Poniachik J, Csendes A, Diaz JC, et al: Increased production of IL-1alpha and TNFalpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine. 33:252–257. 2006. View Article : Google Scholar
26	Tomita K, Tamiya G, Ando S, et al: Tumour necrosis factor alpha signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 55:415–424. 2006. View Article : Google Scholar
27	Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A and George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin. Hepatology. 40:46–54. 2004. View Article : Google Scholar : PubMed/NCBI
28	Lanzilli G, Cottarelli A, Nicotera G, Guida S, Ravagnan G and Fuggetta MP: Anti-inflammatory effect of resveratrol and polydatin by in vitro IL-17 modulation. Inflammation. 35:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
29	Wang X, Song R, Bian HN, Brunk UT, Zhao M and Zhao KS: Polydatin protects arterial smooth muscle cells against mitochondrial dysfunction and lysosomal destabilization following hemorrhagic shock. Am J Physiol Regul Integr Comp Physiol. Jan 25–2002.(Epub ahead of print).
30	Shimano H: Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 40:439–452. 2001. View Article : Google Scholar
31	Raghow R, Yellaturu C, Deng X, Park EA and Elam MB: SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab. 19:65–73. 2008. View Article : Google Scholar : PubMed/NCBI
32	Yan D, Lehto M, Rasilainen L, et al: Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. Arterioscler Thromb Vasc Biol. 27:1108–1114. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T and Yoshikawa T: Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 277:19353–19357. 2002. View Article : Google Scholar : PubMed/NCBI
34	Shimomura I, Bashmakov Y and Horton JD: Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 274:30028–30032. 1999. View Article : Google Scholar : PubMed/NCBI
35	Ahmed MH and Byrne CD: Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 12:740–747. 2007. View Article : Google Scholar : PubMed/NCBI
36	Ntambi JM, Miyazaki M, Stoehr JP, et al: Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci USA. 99:11482–11486. 2002. View Article : Google Scholar : PubMed/NCBI
37	Shrestha S, Ehlers SJ, Lee JY, Fernandez ML and Koo SI: Dietary green tea extract lowers plasma and hepatic triglycerides and decreases the expression of sterol regulatory element-binding protein-1c mRNA and its responsive genes in fructose-fed, ovariectomized rats. J Nutr. 139:640–645. 2009. View Article : Google Scholar
38	Saltiel A and Kahn CR: Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 414:799–806. 2001. View Article : Google Scholar : PubMed/NCBI
39	Browning J and Horton J: Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 114:147–152. 2004. View Article : Google Scholar : PubMed/NCBI
40	Utzschneider KM and Kahn SE: Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 91:4753–4761. 2006. View Article : Google Scholar : PubMed/NCBI
41	Previs SF, Withers DJ, Ren JM, White MF and Shulman GI: Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. J Biol Chem. 275:38990–38994. 2000. View Article : Google Scholar : PubMed/NCBI
42	Samuel VT, Liu ZX, Qu X, et al: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem. 279:32345–32353. 2004. View Article : Google Scholar : PubMed/NCBI